Leisha Emens
Medical Oncology · Baltimore, MDNPI 1003845132
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. F. Hoffmann-la Roche AG accounts for 70.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $33,650 and has fallen 99.6% since, to $145 in 2024.
Across 41 payments — averaging $1057.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$30K
- Shionogi Inc$4K
- Chugai Pharmaceutical Co., Ltd.$3K
- AstraZeneca$3K
- Gilead$3K
- Genentech USA, Inc.$372
- plus $182 from 3 others
Across 171 payments — averaging $7091.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$376K
- Hoffmann-la Roche Limited$321K
- AstraZeneca$259K
- Takeda Pharmaceuticals U.S.A., Inc.$88K
- Merck$58K
- AbbVie$35K
- plus $75K from 3 others
What the payments were for
- Consulting fees$12,38029%
- Speaking & faculty fees$22,92653%
- Travel & lodging$7,04216%
- Food & beverage$9902%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 29 | $30,405 |
| Shionogi Inc | 1 | $4,000 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $2,970 |
| AstraZeneca | 1 | $2,775 |
| Gilead | 2 | $2,647 |
| Genentech USA, Inc. | 4 | $372 |
| Iovance Biotherapeutics, Inc. | 1 | $145 |
| Genentech, Inc. | 1 | $24 |
| Seagen Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,350 in reported general payments places this provider in the 80th percentile of 180 medical oncology providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 11 | $308 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Baltimore
- Mario EisenbergerBaltimore$2.9M
- David SidranskyBaltimore$520K
- Carole MillerBaltimore$331K
- Mark LevisBaltimore$323K
- Tanguy Lim-SeiwertBaltimore$301K
- Shruti ChaturvediBaltimore$265K
- Sandy KotiahBaltimore$247K
- Bruce SmithBaltimore$235K
- Evan LipsonBaltimore$228K
- Nilofer AzadBaltimore$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.